Predictors of adalimumab drug survival in psoriasis differ by reason for discontinuation: long-term results from the Bio-CAPTURE registry

BackgroundDrug survival is an indicator for treatment success; insight in predictors associated with drug survival is important. Objectives (I)To analyse the long-term drug survival for adalimumab in patients with psoriasis treated in daily practice and (II) to identify predictors of prolonged drug survival for adalimumab split for different reasons of discontinuation. MethodsData were extracted from a prospective psoriasis cohort and analysed using Kaplan-Meier survival curves split for reasons of discontinuation. Baseline predictors associated with longer drug survival were identified using multivariate Cox-regression analysis. ResultsOne hundred and sixteen patients were included with a total of 208 patient-years. Overall drug survival was 76% after 1year and 52% after 4.5years. In patients who stopped due to ineffectiveness, longer drug survival was associated with the absence of specific comorbidities (P=0.03). In patients who stopped due to side-effects, longer drug survival was associated with male gender (P=0.02). ConclusionsPredictors of adalimumab drug survival in psoriasis differ by reason for discontinuation. Strong, specific predictors can lead to patient-tailored treatment.